Anti-angiogenic agent ramucirumab: Meaningful or marginal?

Expert Review of Anticancer Therapy

Volumn 14, Issue 4, 2014, Pages 367-379

  Wadhwa, Roopma ^a   Elimova, Elena ^a   Shiozaki, Hironori ^a   Sudo, Kazuki ^a   Blum, Mariela A ^a   Estrella, Jeannelyn S ^a   Chen, Qiongrong ^a   Song, Shumei ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

advanced gastric cancer; angiogenesis; breast cancer; cost benefit; IMC 1121B; ramucirumab; VEGF

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACARBAZINE; DOCETAXEL; ERIBULIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; VANDETANIB; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ADVANCED CANCER; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTERIAL THROMBOEMBOLISM; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIFFERENTIATED THYROID CANCER; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MELANOMA; MOUSE MODEL; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION; TUMOR XENOGRAFT; VENOUS THROMBOEMBOLISM; VOMITING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84896941352     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.896207     Document Type: Article

References (67)

1. Johnson DR, Leeper HE, Uhm JH. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis. Cancer 2013; 119(19):3489-95
2. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14(1):29-37
3. Escudier B, Cosaert J, Pisa P. Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma. Expert Rev Anticancer Ther 2008;8(10):1545-57
4. Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/ carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010;5(9): 1416-23
5. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742): 687-97
6. Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009;19(5):329-37
7. Patel-Hett S, DAmore PA. Signal transduction in vasculogenesis and developmental angiogenesis. Int J Dev Biol 2011;55(4-5):353-63
8. Spratlin JL, Mulder KE. Ramucirumab. Anti-VEGFR-2 human monoclonal antibody antiangiogenic. Drugs Fut 2012; 37(7):483
9. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21): 1182-6
10. Cao Y, Arbiser J, DAmato RJ, et al. Forty-year journey of angiogenesis translational research. Sci Transl Med 2011; 3(114):114rv113
11. Azzi S, Hebda JK, Gavard J. Vascular permeability and drug delivery in cancers. Front Oncol 2013;3:211
12. Liu Z, Fan F, Wang A, et al. Dll4-Notch signaling in regulation of tumor angiogenesis. J Cancer Res Clin Oncol 2013. [Epub ahead of print]
13. Cao Y, Langer R. Optimizing the delivery of cancer drugs that block angiogenesis. Sci Transl Med 2010;2(15):15ps13
14. Cao Y. Off-tumor target-beneficial site for antiangiogenic cancer therapy? Nat Rev Clin Oncol 2010;7(10):604-8
15. Kang JH, Lee SI, Lim do H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30(13):1513-18
16. Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014;15(1):78-86
17. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer- a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47(15):2306-14
18. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94(6): 715-25
19. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24(33):5201-6
20. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29(30): 3968-76
21. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;30(17): 2119-27
22. Lieu CH, Tran H, Jiang Z-Q, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One 2013;8(10):e77117
23. Tabrizi, MA Bornstein GG, Klakamp SL. editors. Development of antibody-based therapeutics: translational considerations. Springer; New York, NY, USA: 2012
24. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499-506
25. Tabernero J, Van Cutsem E, Lakomy R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014; 50(2):320-31
26. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2):115-24
27. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501-13
28. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6): 1061-8
29. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379(9829): 1879-86
30. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2): 125-34
31. Brose MS, Nutting CM, Sherman SI, et al. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349
32. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4): 378-90
33. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134-41
34. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931-9
35. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31(4):412-19
36. Hescot S, Vignaux O, Goldwasser F. France Pancreatic Atrophy - A New Late Toxic Effect of Sorafenib. N Engl J Med 2013; 369(15):1475-6
37. Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol 2010;6(7): 1085-94
38. Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009;10(6):597-605
39. Cao Y. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug? Int J Dev Biol 2011;55(4-5):557-62
40. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28(5): 780-7
41. Franklin MC, Navarro EC, Wang Y, et al. The structural basis for the function of two anti-VEGF receptor 2 antibodies. Structure 2011;19(8):1097-107
42. Lu D, Jimenez X, Zhang H, et al. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 2002; 97(3):393-9
43. Zhu AX, Finn RS, Mulcahy M, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013;19(23):6614-23
44. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2013;383(9911):31-9
45. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 2010;30(6):591-601
46. Mackey JR, Ramos-Vasquez M, Lipatov O, et al. Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. Presented at: the 36th Annual San Antonio Breast Cancer Symposium held December 10-14, 2013, San Antonio, TX. Abstract S5-04
47. US FDA Grants Lillys ramucirumab priority review as a potential single-agent treatment for advanced gastric cancer. Available from: http://newsroom.lilly.com/ releasedetail.cfm?releaseid=799222
48. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 2012;30(32):4026-34
49. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603
50. Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 2010;1(1):12-25
51. Moreno Garcia V, Basu B, Molife LR, Kaye SB. Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 2012;18(14): 3750-61
52. Goyal J, Nuhn P, Huang P, et al. The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. BJU Int 2012;110(11 Pt B):E575-82
53. Templeton AJ, Vera-Badillo FE, Wang L, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013;24(12): p2972
54. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004;351(4):317-19
55. Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007;11(12):1-128. iii-v
56. Hoyle M, Crathorne L, Peters J, et al. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess 2013;17(14):1-237
57. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009;27(23):3868-74
58. Clement FM, Harris A, Li JJ, et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009; 302(13):1437-43
59. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000;283(16):2116-21
60. Berry SR, Bell CM, Ubel PA, et al. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol 2010;28(27):4149-53
61. Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19(4):422-37
62. Ebara T, Ohno T, Nakano T. Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan. DARU 2013;21(1):40
63. Yabroff KR, Schrag D. Challenges and opportunities for use of cost-effectiveness analysis. J Natl Cancer Inst 2009;101(17): 1161-3
64. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863): 303-12
65. pan-Canadian Oncology Drug Review. Available from: www.pcodr.ca/
66. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/ metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12(6): 713-18
67. Moen MD. Bevacizumab: in previously treated glioblastoma. Drugs 2010;70(2): 181-9.